Pomalidomide-C5-Dovitinib

N/A

Report date: 2023/12/14 18:18:37
NME

Base Information

Drug NamePomalidomide-C5-Dovitinib
Drug Alias NamePomalidomide-C5-Dovitinib
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)Small molecules > Molecular Glue
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsStem cell growth factor receptor inhibitorsProteolysis
TargetsTyrosine-protein kinase receptor FLT3Stem cell growth factor receptor
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNankai University
China Registration ClassN/A

Develop Information

Active CompaniesNankai University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A